RP-6503

N/A

Report date: 2023/02/19 22:08:05
NME

Base Information

Drug NameRP-6503
Drug Alias NameRP-6503
ClassificationSmall molecules
Mechanisms of ActionPhosphatidylinositol 3 kinase gamma inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsImmunomodulators
TargetsPhosphatidylinositol 3 kinase deltaPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIncozen Therapeutics Pvt LtdRhizen Pharmaceuticals Sa
China Registration ClassN/A

Develop Information

Active CompaniesIncozen Therapeutics Pvt LtdRhizen Pharmaceuticals Sa
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A